5-day preoperative radiation for soft tissue sarcoma
Official title: Phase 2 5-Day Preoperative Radiation for Soft Tissue Sarcoma
Run by Stanford University · NCT06087861 · Data updated 2026-11-12
This study tests whether a shorter, five-day radiation treatment before surgery can safely help people with soft tissue sarcoma in their arms, legs, or abdomen just as well as the usual longer treatment.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 75 (estimated) |
| Sponsor | Stanford University Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Palo Alto, California) |
| Status | Recruiting |
| Started | October 6, 2023 |
| Main results expected | December 2027 |
| Study ends | December 2029 |
| Registry record updated | June 10, 2026 |
| Trial ID | NCT06087861 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates include adults aged 18 and older with histologically confirmed soft tissue sarcoma who are scheduled for preoperative radiation and surgery.
✕Probably not a fit
Patients with a history of prior radiation to the treatment area or those currently undergoing other anti-cancer therapies may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the safety and effectiveness of a shortened, five-day course of preoperative radiation therapy for patients diagnosed with soft tissue sarcoma located in the extremities, trunk, or retroperitoneum. This approach contrasts with the traditional 25-day radiation regimen, aiming to determine if a more condensed treatment can yield similar or improved outcomes. Participants will receive external beam radiotherapy as part of their preoperative care before surgical intervention.
Why it matters
Potential benefit: If successful, this study could lead to a more efficient and less burdensome preoperative treatment option for patients with soft tissue sarcoma.
How similar studies have gone: While the approach of abbreviated radiation therapy is being explored in various contexts, this specific five-day regimen for soft tissue sarcoma is relatively novel and has not been extensively tested in prior studies.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Histologically confirmed soft tissue sarcoma of the extremity, trunk or retroperitoneum. 2. Has been offered preoperative radiation and surgery as part of standard-of-care treatment 3. Age ≥ 18 4. KPS ≥ 70 or ECOG 0 to 2 5. Life expectancy ≥ 6 months 6. If a woman is of childbearing potential, a negative serum or urine pregnancy test must be documented. 7. Ability to understand and the willingness to personally sign the written IRB approved informed consent document. Exclusion Criteria: 1. History of prior radiation to the area to be treated. 2. Active use of other anti-cancer investigational agents. 3. Planned use of concurrent chemotherapy, targeted therapy, or immunotherapy with radiation therapy (defined as the time interval starting 1 week before the first and last fraction of radiation therapy and surgery). 4. Pregnancy.
Where it's running
-
Stanford University
Palo Alto, California, United States Recruiting
Study contacts
- Principal investigator: Anusha Kalbasi, MD — Stanford University
- Study coordinator: Alyssa Yauger
- Email: ayauger@stanford.edu
- Phone: 650-498-5271
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
68Ga-HX01 PET/CT Imaging in Soft Tissue Sarcoma patients
This study tests whether a 68Ga-HX01 injection can help PET/CT imaging better characterize soft tissue sarcoma in adults who have exhausted standard treatments or have no good options.
-
Zemetostat plus Anlotinib for SWI/SNF-deficient Head and Neck Soft Tissue Sarcoma
This trial tests whether zemetostat plus anlotinib can help people with recurrent or metastatic head-and-neck soft tissue sarcoma that has SWI/SNF complex deficiency after standard therapy fails.
-
Entinostat for pediatric soft tissue sarcoma with PAX abnormalities
This study tests entinostat, alone or with chemotherapy, in children whose soft tissue sarcomas have PAX-family gene abnormalities to see if it can help shrink tumors or slow progression.
-
Methionine-Reduced Diet in Solid Tumors (early-phase)
A small pilot study will test whether a methionine-reduced diet can change blood levels in adults with various solid tumors who are receiving standard cancer therapy.
-
Preoperative Immunonutrition for bone and soft tissue sarcoma patients
This study tests whether a short course of an oral nutrition supplement before surgery can help patients with bone or soft tissue sarcomas recover better after major tumor-related surgery.
-
Adaptive Proton Therapy for Pediatric Solid Tumors and Hodgkin Lymphoma
This study tests a regular imaging approach to see if proton therapy plans for children with solid tumors or Hodgkin lymphoma should be updated during treatment.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.